Avalo Therapeutics AVTX Derivative Liabilities (Non-Current)
Derivative Liabilities (Non-Current) at other companies
Other financials
Where this comes from
Reported directly by Avalo Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:DerivativeLiabilitiesNoncurrent.
The official record: Avalo Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Avalo Therapeutics's derivative liabilities (non-current).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Avalo Therapeutics's derivative liabilities (non-current)?
- Avalo Therapeutics (AVTX) reported derivative liabilities (non-current) of $17.52M in Q1 2026.
- How has Avalo Therapeutics's derivative liabilities (non-current) changed year-over-year?
- Avalo Therapeutics's derivative liabilities (non-current) increased by 126.4% year-over-year, from $7.74M to $17.52M.
- What does derivative liabilities (non-current) mean?
- This represents the fair value of long-term financial instruments, such as warrants or embedded derivatives, that are classified as liabilities and are not expected to be settled within the next twelve months. These instruments often arise from complex financing arrangements or equity-linked agreements common in biotechnology capital structures. Changes in this balance reflect the valuation impact of market conditions and the company's long-term financial risk profile.